Survival of People Living with HIV/AIDS from Pre-ART Era to Treat-all Era - China, 1985-2022

Overview

Journal China CDC Wkly

Date 2024 Dec 19

PMID 39698325

Authors

Shi Wang

Houlin Tang

Decai Zhao

Chang Cai

Yichen Jin

Qianqian Qin

Fangfang Chen

Liping Fei

Hehe Zhao

Zhongnian Yang

Fan Lyu

Affiliations

Soon will be listed here.

Abstract

Introduction: A comprehensive analysis of nationwide survival trends for people living with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS, PLWHA) from the initial reported case to present has not been conducted. This study evaluated the survival outcomes of PLWHA reported in China from 1985 to 2022.

Methods: We analyzed data from PLWHA recorded in the National HIV/AIDS Comprehensive Response Information Management System from 1985 to 2022. Survival rates were calculated using Kaplan-Meier curves, and factors associated with survival time were analyzed using Cox proportional hazard models.

Results: Progressive relaxation of antiretroviral therapy initiation criteria led to significant improvements in survival rates across different diagnostic periods in China. The 1-year and 5-year cumulative survival rates increased from 85.2% and 66.1% in the 1985-2003 cohort to 91.1% and 81.4% in the 2016-2022 cohort. Cox proportional hazard analysis revealed elevated mortality risks among males, individuals aged ≥65 years, those with injection drug use or other transmission routes, hospital-tested patients, and those with lower CD4 counts at diagnosis or without treatment.

Conclusions: Antiretroviral therapy has effectively reduced mortality risk among PLWHA in China. Future efforts should focus on expanding HIV testing to reduce the proportion of late diagnoses with lower CD4 counts and providing targeted, differentiated services for older populations to further decrease mortality risk among PLWHA.

References

Lai S, Chen J, Celentano D, Page J, Lai H, Yang J . Adoption of injection practices in heroin users in Guangxi Province, China. J Psychoactive Drugs. 2000; 32(3):285-92. DOI: 10.1080/02791072.2000.10400451. View

Kitahata M, Gange S, Abraham A, Merriman B, Saag M, Justice A . Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18):1815-26. PMC: 2854555. DOI: 10.1056/NEJMoa0807252. View

Park B, Choi Y, Kim J, Seong H, Kim Y, Lee M . Mortality and Causes of Death among Individuals Diagnosed with Human Immunodeficiency Virus in Korea, 2004-2018: An Analysis of a Nationwide Population-Based Claims Database. Int J Environ Res Public Health. 2022; 19(18). PMC: 9517230. DOI: 10.3390/ijerph191811788. View

Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M . Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130-9. DOI: 10.1093/cid/cir626. View

Ke S, Fang Q, Lan J, Qiao N, Zhang X, Xie C . Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China. BMC Public Health. 2023; 23(1):1745. PMC: 10483872. DOI: 10.1186/s12889-023-15662-3. View

Braunstein S, Kersanske L, Torian L, Lazar R, Harriman G . Survival Among New Yorkers with HIV from 1981 to 2017: Inequities by Race/Ethnicity and Transmission Risk Persist into the Post-HAART Era. AIDS Behav. 2021; 26(1):284-293. PMC: 8449215. DOI: 10.1007/s10461-021-03382-x. View

Zhang X, Wang N, Vermund S, Zou H, Li X, Zhang F . Interventions to improve the HIV continuum of care in China. Curr HIV/AIDS Rep. 2019; 16(6):448-457. PMC: 10767704. DOI: 10.1007/s11904-019-00469-y. View

Zhang L, Qiao X, Nie X, Guo X, Mei Z . [A retrospective cohort study on the survival of blood-borne human immunodeficiency virus cases in a county, China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2005; 25(11):941-4. View

Castillo-Rozas G, Tu S, Luz P, Mejia F, Sierra-Madero J, Rouzier V . Clinical outcomes and risk factors for immune recovery and all-cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study. J Int AIDS Soc. 2024; 27(3):e26214. PMC: 10945036. DOI: 10.1002/jia2.26214. View

10.

Manosuthi W, Charoenpong L, Santiwarangkana C . A retrospective study of survival and risk factors for mortality among people living with HIV who received antiretroviral treatment in a resource-limited setting. AIDS Res Ther. 2021; 18(1):71. PMC: 8513274. DOI: 10.1186/s12981-021-00397-1. View

11.

Kamya M, Petersen M, Kabami J, Ayieko J, Kwariisima D, Sang N . SEARCH Human Immunodeficiency Virus (HIV) Streamlined Treatment Intervention Reduces Mortality at a Population Level in Men With Low CD4 Counts. Clin Infect Dis. 2021; 73(7):e1938-e1945. PMC: 8492199. DOI: 10.1093/cid/ciaa1782. View

12.

Zhao Y, Wei L, Dou Z, Zhao D, Gan X, Wu Y . Changing Mortality and Patterns of Death Causes in HIV Infected Patients - China, 2013-2022. China CDC Wkly. 2023; 5(48):1073-1078. PMC: 10696223. DOI: 10.46234/ccdcw2023.201. View

13.

Tsuda H, Koga M, Nojima M, Senkoji T, Kubota M, Kikuchi T . Changes in survival and causes of death among people living with HIV: Three decades of surveys from Tokyo, one of the Asian metropolitan cities. J Infect Chemother. 2021; 27(7):949-956. DOI: 10.1016/j.jiac.2021.02.003. View